1Singhal S. Mehtaj,Desikan Retal Anti-tumor activity of thalidomide in refractory Multiple Myeloma, N Engl J Med 1999,341(1):1565.
2Renller,A, Roanan,P,Hardan I et al therary with thalidomide in refractory mutiple myeloma Patientsthe revial of an olddray Br J Henatol,2000,108(2):391.
2[1]Sezer O, Niemoller K, Eucker J, et al. Bone marr ow microvessel density is a prognostic factor for survival in patients with mult iple myeloma. Ann Hematol, 2000, 24:574-576.
3[2]Perez-Atayde A, Sallan S, Tedrow U, et al. Spectrum of tumor angio genesis in the bone marrow of children with acute lymphoblastic leukemia. Am J P hthol, 1997,150:815-821.
4[3]Shami P J, Hussong J W, Rodgers G M. Evidence of increased angiogenesi s in the bone marrow of patients with acute nonlymphocytic leukemia. Blood,1998, 92(suppl, 1):512-513.
5[4]Bellamy W T, Ritchter L, Frutiger Y, et al. Expression of VEGF and its receptors in hematopoietic malignancies. Cancer Res, 1999, 59:728-733.
7[6]Singhal S, Mehta J, Desikam R, et al. Antitumor activity of thalidomid e in refractory multiple myeloma . N Engl J Med, 1999, 341:1565-1571.
8[7]Verheul H M, Panigraphy D, Yuan J, et al. Combination oral antiangioge nic therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Br J Cancer, 1999, 79:114-118.
9[8]Liu J, Razani B, Tang S, et al. Angiogenesis activators and inh ibitors differently regulate caveolin-1 expression and caveolae formation in va scular endothelial cells angiogenesis inhibitors block vascular endothelial grow th factor-induced down-regulation of caveolin-1. J Biol Chem, 1999, 274:15781 -15785.
10[9]Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs o vercome drug resistance of human multiple mueloma cells to conventional therapy. Blood, 2000, 96:2943-2950.
